THERAPY DOSSIER · th-b3f51b7e1c80

L-2-oxothiazolidine-4-carboxylate (oxothiazolidine carboxylate)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL442218 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Procysteine; Koprosteine; L-2-oxo-4-thiazolidinecarboxylic acid; L-2-oxothiazolidine-4-carboxylic acid; Oxothiazolidinecarboxylic acid
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00002114 ↗PHASE2completed

Trial title not recorded

HIV Infections

Enrolment: 125 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 2606838 ↗1989Reported benefit

Modulation of endoperoxide product levels and cyclophosphamide-induced injury by glutathione repletion.

RatChemical/toxinF344MaleCoadministered with cyclophosphamide

Model: Cyclophosphamide-induced acute lung injury

Cyclophosphamide caused dose-dependent depletion of pulmonary glutathione and increased lavage albumin. Coadministration of oxothiazolidine carboxylate reversed glutathione depletion, abrogated the acute lung injury and variably reversed the changes in prostaglandin E2 and thromboxane concentration…

Extraction: extract · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.

Loading the evidence…